No abstract

oncologists. Logistic regression models were used to identify patient factors associated with choosing ET regimens only.Results: For patients (n¼300) and oncologists (n¼200) across both DCEs, improving iDFS was most important (1.5-4 times more important than the next most important attribute), followed by neutropenia and diarrhea risk for patients and oncologists, respectively. Dosing schedule, alopecia risk, and ECG monitoring were typically least important for both groups. More patients (24%) than oncologists (9%) selected ET exclusively over CDK4/6i + ET. Patient factors associated with selecting ET monotherapy included natural menopause (vs. induced/premenopausal), stage II (vs. stage III) BC, and not college educated.Conclusions: Patients and oncologists were generally willing to accept increased risks of adverse events with combination CDK4/6i regimens in exchange for improved iDFS. However, patients placed relatively higher importance on safety-related attributes, emphasizing the need for clinicians to communicate and manage potential adverse events with patients to support them in achieving their treatment goals in early BC.

No abstract

No abstract